Valuation: iTeos Therapeutics, Inc.

Market Cap 449M 399M 372M 339M 640M 43.13B 646M 4.5B 1.74B 22.05B 1.68B 1.65B 70.77B P/E 2023
-3.48x
P/E 2024 -2.31x
Enterprise Value -40.87M -36.31M -33.89M -30.89M -58.26M -3.93B -58.8M -410M -159M -2.01B -153M -150M -6.45B EV / Sales 2023
-10,640,152x
EV / Sales 2024 -5,970,615x
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Executive Officer 59 27/08/2025
Chief Operating Officer - 27/08/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 59 27/08/2025
Date Insider Type Main position Quantity % Market Cap. Importance
29/08/25 Tender

Chief Technology Officer

222,423 0.5811%
29/08/25 Tender

Chief Executive Officer; Director

1,106,638 2.8914%
29/08/25 Tender

Chief Operating Officer

578,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--%-.--%-3.70% 449M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.18%-0.53%+47.37%+115.32% 39.1B
Weighted average by Cap. +0.12%-0.84%+56.89%+138.10%

Financials

2023 2024
Net sales 12.6 11.19 10.44 9.52 17.95 1.21K 18.12 126.4 48.98 618.97 47.29 46.26 1.99K 35 31.1 29.02 26.45 49.89 3.36K 50.36 351.25 136.11 1.72K 131.41 128.56 5.52K
Net income -113M -100M -93.41M -85.14M -161M -10.83B -162M -1.13B -438M -5.54B -423M -414M -17.77B -134M -119M -111M -102M -192M -12.92B -193M -1.35B -523M -6.61B -505M -494M -21.2B
Net Debt -526M -467M -436M -397M -750M -50.55B -757M -5.28B -2.04B -25.84B -1.97B -1.93B -82.94B -490M -435M -406M -370M -698M -47.06B -704M -4.91B -1.9B -24.06B -1.84B -1.8B -77.21B
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock